Integra Lifesciences Holdings (IART) Non-Current Deferred Tax Liability (2009 - 2026)

Integra Lifesciences Holdings has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $3.5 million in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability fell 94.22% year-over-year to $3.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 million (down 94.22% YoY) and the FY2025 annual result came in at $5.7 million, down 97.85% from the prior year.
• Non-Current Deferred Tax Liability fell to $3.5 million in Q2 2026 per IART's latest filing, from $6.1 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $263.4 million in Q4 2024 and troughed at $3.5 million in Q2 2026.
• A 5-year average of $81.7 million and a median of $61.5 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 83.2% in 2025, down 97.85% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $218.3 million in 2022, then dropped by 0.87% to $216.4 million in 2023, then grew by 21.72% to $263.4 million in 2024, then tumbled by 97.85% to $5.7 million in 2025, then sank by 38.74% to $3.5 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.5 million, $6.1 million, and $5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.